Off-Target Effects of BCR-ABL and JAK2 Inhibitors
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference117 articles.
1. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.;Tefferi;J Clin Oncol,2011
2. Lessons learned from the development of imatinib.;Lydon;Leuk Res,2004
3. . Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).;Hughes;Blood,2010
4. . Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.;Winter;Nat Chem Biol,2012
5. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.;Rowley;Nature,1973
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Delineating Drug Class and Target-Specific Adverse Events of Kinase Inhibitors;2024-08-08
2. Discovery of conformationally constrained c-Abl inhibitors with potential neuroprotective effects against Parkinson’s disease;Bioorganic & Medicinal Chemistry;2023-12
3. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways;Cell Communication and Signaling;2023-10-16
4. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases;Rheumatology;2023-08-25
5. A Novel highly selective allosteric inhibitor of TYK2 can block inflammation/autoimmune pathways;2023-06-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3